Sa-β-galactosidase-based screening assay for the identification of senotherapeutic drugs

Heike Fuhrmann-Stroissnigg, Fernando E. Santiago, Diego Grassi, Yuan Yuan Ling, Laura J. Niedernhofer, Paul D. Robbins

Research output: Contribution to journalArticle

Abstract

Cell senescence is one of the hallmarks of aging known to negatively influence a healthy lifespan. Drugs able to kill senescent cells specifically in cell culture, termed senolytics, can reduce the senescent cell burden in vivo and extend healthspan. Multiple classes of senolytics have been identified to date including HSP90 inhibitors, Bcl-2 family inhibitors, piperlongumine, a FOXO4 inhibitory peptide and the combination of Dasatinib/Quercetin. Detection of SA-β-Gal at an increased lysosomal pH is one of the best characterized markers for the detection of senescent cells. Live cell measurements of senescence-associated β-galactosidase (SA-β-Gal) activity using the fluorescent substrate C12FDG in combination with the determination of the total cell number using a DNA intercalating Hoechst dye opens the possibility to screen for senotherapeutic drugs that either reduce overall SA-β-Gal activity by killing of senescent cells (senolytics) or by suppressing SA-β-Gal and other phenotypes of senescent cells (senomorphics). Use of a high content fluorescent image acquisition and analysis platform allows for the rapid, high throughput screening of drug libraries for effects on SA-β-Gal, cell morphology and cell number.

Original languageEnglish (US)
Article numbere58133
JournalJournal of Visualized Experiments
Volume2019
Issue number148
DOIs
StatePublished - Jun 2019

Keywords

  • Aging
  • Biology
  • Cell Death
  • Cell Senescence
  • High Throughput Screening
  • Issue 148
  • Senescence Associated β-Galactosidase
  • Senolytics
  • Senomorphics
  • Senotherapeutics

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Video-Audio Media

Fingerprint Dive into the research topics of 'Sa-β-galactosidase-based screening assay for the identification of senotherapeutic drugs'. Together they form a unique fingerprint.

  • Cite this